Chesapeake Research Group is Enrolling Patients for a Clinical Study of a Non-Opioid Medication that Could Help Combat the Opioid Epidemic
BALTIMORE, July 30, 2018 /PRNewswire/ -- Chesapeake Research Group, CRG, is currently enrolling patients in a clinical research study for an investigational medication used to treat post-operative pain. The new medication could help combat America's opioid epidemic.
America's opioid epidemic is taking lives and destroying families at an alarming pace. Each year, over 100 million surgeries are conducted in the U.S. alone. Of those surgeries, roughly 30 million require prescription (non-over-the-counter (OTC) pain management. Frequently, in these cases, patients are prescribed opioids. For many struggling with opioid dependency, this post-surgical pain management was the gateway to their opioid addiction. This investigational medicine could greatly reduce or even eliminate the need for physicians to prescribe opioids postoperatively. In turn, reducing the likelihood of developing opioid dependency or possibly preventing patients from being exposed to opioids completely.
"After almost 20 years of investigating new approaches to treating pain, this particular study stands out. The product we are testing is a water-soluble non-opioid substance that rapidly converts to capsaicin, which selectively desensitizes pain conducting nerve fibers to provide long-lasting pain relief," said Dr. Ira Gottlieb, Medical Director of CRG. "We insert the purified product into the surgical site prior to completing the operation. Capsaicin is a naturally occurring compound found in spicy peppers. It has been used for many years in OTC products to treat various painful conditions such as arthritis and nerve pain from shingles and neuropathy. "
CRG is enrolling patients who suffer from discomfort due to bunion pain. If selected for the study, patients will undergo a bunionectomy at CRG's facility. Patients receive the surgery at no cost and may be compensated for time and travel.
CRG works alongside pharmaceutical companies that are developing medications to reduce the need for opioids after surgery or to eliminate their use altogether. It was founded in 2004 by Dr. Ira J. Gottlieb and Deborah Tunick, RN, CCRC. The clinical study investigative site is dedicated to supporting its clients in the development of products by conducting rigorous and efficient clinical drug/ device studies. CRG has completed over 60 pain related studies in its 10,0000-square foot state-of-the-art facility in Pasadena Maryland. The facility encompasses their Research Facility, Surgery Centers and Foot & Ankle Center. The facility has multiple treatment rooms and overnight capabilities for 15 research participants.
Dr. Ira J. Gottlieb